Last reviewed · How we verify
Kalinox 170 bar
Kalinox 170 bar is a Small molecule drug developed by Air Liquide Santé International. It is currently FDA-approved.
Kalinox 170 bar is a small molecule intervention used in clinical trials for various conditions, including liver biopsy, burns, cancer, pain, and dental care. It is administered as a 50% nitrous oxide and 50% oxygen premix, and has been studied in at least one clinical trial, specifically for use during liver biopsy of focal lesions.
At a glance
| Generic name | Kalinox 170 bar |
|---|---|
| Sponsor | Air Liquide Santé International |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of the Efficacy of Kalinox® 170 Bar in Adult Oncology (PHASE4)
- Use of 50% Nitrous Oxide / 50% Oxygen Premix in Primary Care Dental Centers (PHASE3)
- Use of 50% Nitrous Oxide / 50% Oxygen Premix During Liver Biopsy of Focal Lesion (PHASE4)
- Study of the Efficacy and Safety of Kalinox® 170 Bar for the Performance of Care Procedures in Children With Burns (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Kalinox 170 bar CI brief — competitive landscape report
- Kalinox 170 bar updates RSS · CI watch RSS
- Air Liquide Santé International portfolio CI
Frequently asked questions about Kalinox 170 bar
What is Kalinox 170 bar?
Who makes Kalinox 170 bar?
What development phase is Kalinox 170 bar in?
Related
- Manufacturer: Air Liquide Santé International — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing